Kenvue Q3 2026: Sales Up 3.2% to $3.8bn, Hair Care Leads Beauty

Kenvue posted net sales of US$3.8bn in Q3 2026, up 3.2%, extending its growth run to a fourth consecutive quarter even as its skin health and beauty segment barely moved — up just 0.1%.

For the first nine months of 2026, the Johnson & Johnson spinoff grew net sales 3.6% to $11.7bn, compared with $11.34bn in the same period last year. Gross profit jumped 4% to $2.3bn, up from $2.2bn in 2025.

The numbers land with real weight for anyone tracking where retail beauty demand sits right now: self-care and essential health carried the quarter, while beauty essentially broke even.

What's behind the beauty segment's flat quarter?

The skin health and beauty division's 0.1% headline increase splits into an organic sales decline of 0.5%, offset by a foreign currency benefit of 0.6%. Strip out the currency tailwind and the segment contracted slightly.

Hair care was the standout exception within that picture, delivering low double-digit organic sales growth. The growth was led by Rogaine, which notched its fourth consecutive quarter of market share gains — a sustained run, not a one-quarter blip, and a signal that scalp and regrowth categories keep pulling consumers in a soft beauty spending environment.

CEO Kirk Perry framed the quarter in execution terms.

"We are pleased to have delivered our fourth consecutive quarter of net and organic sales growth, with strong performance in self-care and essential health, along with margin expansion and strong cash generation," he said. "Our results reflect continued momentum from disciplined execution, ongoing productivity initiatives, and investment in our brands and innovation."

In plain terms: the growth engine is the health side of the portfolio, with hair care doing the heavy lifting inside beauty.

Neutrogena's new UV filter hits shelves

The quarter's most concrete product story sits in North America sun care. Last month, Kenvue launched Neutrogena Cloud Tech featuring BEMT (bemotrizinol) — the brand's first sunscreen technology built on the new FDA-approved UV filter.

That formulation detail matters for the trade. Bemotrizinol has long been used in European and Asian sun care formulas; its FDA approval gives US brands access to a modern broad-spectrum filter, and Neutrogena moved quickly to build a line around it. Early shelf expansion of North America sun care contributed to the quarter, per the company.

Where does the Kimberly-Clark deal stand?

The Q3 update follows Kenvue's acquisition by Kimberly-Clark in a $48.7bn deal announced last year. Once closed, Kenvue's health and beauty brands — Neutrogena, Aveeno, OGX and Listerine — will sit under the same corporate umbrella as Kimberly-Clark's personal care portfolio.

Because the transaction is pending, Kenvue withheld forward-looking guidance for the year in this quarterly update — a deliberate omission, not a red flag on its own.

Perry signaled the deal is close to the finish line.

"As we near the completion of our value-creating combination with Kimberly-Clark and bring together our two companies, the team is excited about the opportunities ahead," he said.

For practitioners and retail buyers, the pending structure means Neutrogena, Aveeno and OGX distribution, marketing spend and shelf strategy could shift once Kimberly-Clark's personal care machine takes over — worth watching as integration begins.

The transformation continues underneath

The quarter's strength rests on a restructuring Kenvue kicked off in July 2025 amid falling sales and job cuts. The strategic review aims to optimise the operating model, transform the supply chain, reduce complexity and drive operational efficiencies, while strengthening core capabilities.

"We are strongly on track to deliver our business transformation that we began last year," Perry said, adding thanks to staff "for their dedication to delighting our consumers and customers, disciplined execution, and delivering what was promised."

The takeaway for the trade: margins expanded, cash generation stayed strong, and hair care — Rogaine especially — remains the one beauty category reliably compounding share. The real test comes post-close, when Kimberly-Clark decides how much firepower sits behind Neutrogena's new BEMT sunscreen line and the OGX and Aveeno hair portfolios.